Scholarlink

Background <p>Exercise is increasingly recognized as a non-pharmacological strategy for cognitive aging; however, comparative evidence across modalities, phenotypes, and doses is limited.</p> Methods <p>We conducted a Bayesian network meta-analysis of 38 randomized controlled trials (<i>N</i> = 4,047; 88 arms). The interventions included aerobic, resistance, multimodal, and other exercise formats compared with non-exercise controls. The primary outcome was global cognition. Analyses were stratified by age (&lt; 70 vs. ≥70 years) and phenotype (healthy vs. pre-sarcopenic). Dose–response relationships were modeled using the weekly volume (MET·min/week).</p> Results <p>Aerobic (standardized mean difference [SMD] 0.58, 95% CI 0.33–0.83), resistance (0.62, 0.35–0.88), and multimodal programs (0.68, 0.40–0.95) significantly improved cognition compared to the control, with smaller effect sizes. Healthy older adults benefited most from aerobic (0.88, 0.55–1.20) and resistance training (0.80, 0.42–1.19), whereas multimodal programs were most effective for pre-sarcopenia (0.60, 0.29–0.90). Dose–response analysis showed clinically meaningful benefits from ~ 600 MET·min/week, with optimal effects between 700 and 1,200 MET·min/week. Higher volumes conferred no consistent additional gains in pre-sarcopenia.</p> Conclusions <p>Exercise is a scalable, safe, and clinically effective approach for preserving late-life cognition. For healthy older adults, aerobic or resistance training at ≥ 600 MET·min/week is recommended; for pre-sarcopenic individuals, multimodal programs at approximately 700–800 MET·min/week offer the best balance of efficacy and sustainability. These findings provide actionable targets for clinicians and policymakers, advancing precision exercise prescriptions for cognitive health in aging populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimal type and dose of exercise to improve cognitive function in healthy and pre-sarcopenic older adults: a bayesian network meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Yong Yang,
  • Neng Pan,
  • Yufei Liu,
  • Weiqiang Xu,
  • Zbigniew Ossowski

摘要

Background

Exercise is increasingly recognized as a non-pharmacological strategy for cognitive aging; however, comparative evidence across modalities, phenotypes, and doses is limited.

Methods

We conducted a Bayesian network meta-analysis of 38 randomized controlled trials (N = 4,047; 88 arms). The interventions included aerobic, resistance, multimodal, and other exercise formats compared with non-exercise controls. The primary outcome was global cognition. Analyses were stratified by age (< 70 vs. ≥70 years) and phenotype (healthy vs. pre-sarcopenic). Dose–response relationships were modeled using the weekly volume (MET·min/week).

Results

Aerobic (standardized mean difference [SMD] 0.58, 95% CI 0.33–0.83), resistance (0.62, 0.35–0.88), and multimodal programs (0.68, 0.40–0.95) significantly improved cognition compared to the control, with smaller effect sizes. Healthy older adults benefited most from aerobic (0.88, 0.55–1.20) and resistance training (0.80, 0.42–1.19), whereas multimodal programs were most effective for pre-sarcopenia (0.60, 0.29–0.90). Dose–response analysis showed clinically meaningful benefits from ~ 600 MET·min/week, with optimal effects between 700 and 1,200 MET·min/week. Higher volumes conferred no consistent additional gains in pre-sarcopenia.

Conclusions

Exercise is a scalable, safe, and clinically effective approach for preserving late-life cognition. For healthy older adults, aerobic or resistance training at ≥ 600 MET·min/week is recommended; for pre-sarcopenic individuals, multimodal programs at approximately 700–800 MET·min/week offer the best balance of efficacy and sustainability. These findings provide actionable targets for clinicians and policymakers, advancing precision exercise prescriptions for cognitive health in aging populations.